Vancouver, B.C., August 10, 2018 – MYM Nutraceuticals Inc., (CSE: MYM) (the “Company” or “MYM”) is pleased to announce the appointment of Elizabeth S. Liu, QC to the Board of Direc-tors effective August 1, 2018. Ms. Liu founded and is Managing Director of LINK Business Law Group, a law firm that provides a broad range of legal, strategic and risk management advice, as well as general counsel services. Her clients include both early-stage and established com-panies in a variety of industries.

Prior to establishing LINK Business Law Group, Ms. Liu was Managing Partner at Basham Thompson & Liu LLP, a boutique litigation firm. She then served as Vice President and General Counsel to the Flora Group of Companies where she was involved in all aspects of the group’s operations and provided guidance on contracts and other legal and risk planning issues. Flora manufactures and sells premium natural health products and has numerous distributorships in international markets.

Ms. Liu was appointed Queen’s Counsel by Order-in-Council in December 2016.

“We are happy to welcome Elizabeth to the MYM family,” said Rob Gietl, CEO of MYM. “Elizabeth brings with her over 25 years of legal and management experience. Her time spent working with the Flora Group of Companies will prove instrumental in creating and distributing new lines of premium cannabis natural health products.”

Ms. Liu was granted options to purchase 100,000 common shares of the Company in accordance with the Company’s stock option plan. The options are exercisable at a price of $1.32 per share. 25,000 options will vest every six months from August 1, 2018. The expiry date of this option is August 1, 2021.

About MYM Nutraceuticals Inc.
MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end medicinal cannabis supplements and topical products. MYM is a shareholder in two production projects in Quebec that are anticipated to have over 1.5 million square feet of production space. MYM is also a shareholder in two additional cannabis production projects in Australia and Colombia. The “Northern Rivers Project” in New South Wales, Australia is expected to have 1.2 million square feet of cannabis production space. In Colombia, MYM partner, Colombia Organica, currently hold a seed to sale license for low THC cannabis and are in the licensing process for the cultivation and production of high THC cannabis extracts. Plans are underway for MYM and Colombia Organica to build a cannabis production facility in the region. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE:MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).

ON BEHALF OF THE BOARD
Rob Gietl, CEO
MYM Nutraceuticals Inc.
www.mym.ca

Investor Relations
Terry Brown
1.855.696.2261
terry.brown@mym.ca

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Cana-dian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the secu-rities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.